Načítá se...

A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts

We have previously shown that repeated sequential administration of doxorubicin, followed 24 h later by zoledronic acid, inhibits tumour growth in models of established breast cancer bone metastasis. As breast cancer patients only receive zoledronic acid every 3–4 weeks, the aim of the current study...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Bone Oncol
Hlavní autoři: Brown, H.K., Ottewell, P.D., Evans, C.A., Coleman, R.E., Holen, I.
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2012
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4723328/
https://ncbi.nlm.nih.gov/pubmed/26909255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2012.05.001
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!